Literature DB >> 26977756

Histology Grade Is Independently Associated With Relapse Risk in Patients With Ulcerative Colitis in Clinical Remission: A Prospective Study.

Talia Zenlea1, Eric U Yee2, Laura Rosenberg1, Marie Boyle1, Kavinderjit S Nanda1, Jacqueline L Wolf1, Kenneth R Falchuk1, Adam S Cheifetz1, Jeffrey D Goldsmith2, Alan C Moss1.   

Abstract

OBJECTIVES: Objective evidence of inflammation has been associated with the risk of relapse in patients with ulcerative colitis (UC) who are in clinical remission. We compared endoscopic and histologic grades for their ability to predict clinical relapse in this patient population.
METHODS: Patients with UC in clinical remission were prospectively enrolled into an observational cohort. Baseline endoscopic scores (Mayo) and histological (Geboes) grades and blood markers were collected. All subjects were followed for 12 months and relapse determined using clinical indices.
RESULTS: A total of 179 subjects were enrolled into the study and followed for 12 months. Clinical relapse occurred in 23%; 5% were hospitalized, and 2% underwent colectomy. In univariate analysis, the baseline Mayo endoscopy score and the Geboes histology grade were significantly associated with the later development of clinical relapse (P<0.001 for both), but only the histology grade remained significant in a multivariate model (P=0.006). The relative risk of clinical relapse was 3.5 (95% CI 1.9-6.4, P<0.0001) in subjects whose baseline Geboes grade was ≥3.1. The area under the curve was 0.73 for the Geboes histology grade to identify subjects at risk of future clinical relapse. Of the patients in clinical, endoscopic, and histological remission at baseline (n=82), only 7% had a clinical relapse over the subsequent 12 months.
CONCLUSIONS: Histology grade has the strongest association with the risk of clinical relapse in patients with UC who are in clinical remission. Consideration should be given to including this end point in evaluating therapy for UC.

Entities:  

Mesh:

Year:  2016        PMID: 26977756     DOI: 10.1038/ajg.2016.50

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  32 in total

Review 1.  Treat to target: a proposed new paradigm for the management of Crohn's disease.

Authors:  Guillaume Bouguen; Barrett G Levesque; Brian G Feagan; Arthur Kavanaugh; Laurent Peyrin-Biroulet; Jean-Frederic Colombel; Stephen B Hanauer; William J Sandborn
Journal:  Clin Gastroenterol Hepatol       Date:  2013-09-10       Impact factor: 11.382

Review 2.  Histologic evaluation of ulcerative colitis: a systematic review of disease activity indices.

Authors:  Mahmoud H Mosli; Brian G Feagan; William J Sandborn; Geert Dʼhaens; Cynthia Behling; Keith Kaplan; David K Driman; Lisa M Shackelton; Kenneth A Baker; John K Macdonald; Margaret K Vandervoort; Karel Geboes; Barrett G Levesque
Journal:  Inflamm Bowel Dis       Date:  2014-03       Impact factor: 5.325

3.  Can mucosal healing be a cost-effective endpoint for biologic therapy in Crohn's disease? A decision analysis.

Authors:  Ashwin N Ananthakrishnan; Joshua R Korzenik; Chin Hur
Journal:  Inflamm Bowel Dis       Date:  2013-01       Impact factor: 5.325

4.  Increased production of tumour necrosis factor-alpha interleukin-1 beta, and interleukin-6 by morphologically normal intestinal biopsies from patients with Crohn's disease.

Authors:  J M Reimund; C Wittersheim; S Dumont; C D Muller; J S Kenney; R Baumann; P Poindron; B Duclos
Journal:  Gut       Date:  1996-11       Impact factor: 23.059

5.  Predictors of endoscopic inflammation in patients with ulcerative colitis in clinical remission.

Authors:  Laura Rosenberg; Garrett O Lawlor; Talia Zenlea; Jeffrey D Goldsmith; Anne Gifford; Kenneth R Falchuk; Jacqueline L Wolf; Adam S Cheifetz; Simon C Robson; Alan C Moss
Journal:  Inflamm Bowel Dis       Date:  2013 Mar-Apr       Impact factor: 5.325

6.  Fecal level of calprotectin identifies histologic inflammation in patients with ulcerative colitis in clinical and endoscopic remission.

Authors:  Jordi Guardiola; Triana Lobatón; Lorena Rodríguez-Alonso; Alexandra Ruiz-Cerulla; Claudia Arajol; Carolina Loayza; Xavier Sanjuan; Elena Sánchez; Francisco Rodríguez-Moranta
Journal:  Clin Gastroenterol Hepatol       Date:  2014-06-30       Impact factor: 11.382

7.  Inflammation is an independent risk factor for colonic neoplasia in patients with ulcerative colitis: a case-control study.

Authors:  David T Rubin; Dezheng Huo; Jami A Kinnucan; Mina S Sedrak; Nicole E McCullom; Alana P Bunnag; Elin P Raun-Royer; Russell D Cohen; Stephen B Hanauer; John Hart; Jerrold R Turner
Journal:  Clin Gastroenterol Hepatol       Date:  2013-07-17       Impact factor: 11.382

8.  Does fecal calprotectin predict short-term relapse after stopping TNFα-blocking agents in inflammatory bowel disease patients in deep remission?

Authors:  Pauliina Molander; Martti Färkkilä; Ari Ristimäki; Kimmo Salminen; Helena Kemppainen; Timo Blomster; Ritva Koskela; Airi Jussila; Henna Rautiainen; Markku Nissinen; Johanna Haapamäki; Perttu Arkkila; Urpo Nieminen; Juha Kuisma; Jari Punkkinen; Kaija-Leena Kolho; Harri Mustonen; Taina Sipponen
Journal:  J Crohns Colitis       Date:  2015-01       Impact factor: 9.071

9.  Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study.

Authors:  Roopali Bansal Gupta; Noam Harpaz; Steven Itzkowitz; Sabera Hossain; Sierra Matula; Asher Kornbluth; Carol Bodian; Thomas Ullman
Journal:  Gastroenterology       Date:  2007-08-02       Impact factor: 22.682

10.  Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalisation over 6 years of follow-up.

Authors:  Robert V Bryant; Daniel C Burger; Joseph Delo; Alissa J Walsh; Sally Thomas; Axel von Herbay; Otto C Buchel; Lydia White; Oliver Brain; Satish Keshav; Bryan F Warren; Simon P L Travis
Journal:  Gut       Date:  2015-05-18       Impact factor: 23.059

View more
  37 in total

1.  IBD: Mucosal healing in ulcerative colitis: what constitutes remission?

Authors:  Robert H Riddell
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-12-07       Impact factor: 46.802

Review 2.  Disease activity and mucosal healing in inflammatory bowel disease: a new role for histopathology?

Authors:  Rish K Pai; Karel Geboes
Journal:  Virchows Arch       Date:  2017-05-30       Impact factor: 4.064

Review 3.  Mucosal Healing in Ulcerative Colitis: A Comprehensive Review.

Authors:  Pedro Boal Carvalho; José Cotter
Journal:  Drugs       Date:  2017-02       Impact factor: 9.546

4.  Complete histologic normalisation is associated with reduced risk of relapse among patients with ulcerative colitis in complete endoscopic remission.

Authors:  Kelly C Cushing; William Tan; David H Alpers; Vikram Deshpande; Ashwin N Ananthakrishnan
Journal:  Aliment Pharmacol Ther       Date:  2019-11-07       Impact factor: 8.171

5.  Evaluating the optimum number of biopsies to assess histological inflammation in ulcerative colitis: a retrospective cohort study.

Authors:  Robert Battat; Niels Vande Casteele; Rish K Pai; Zhongya Wang; Guangyong Zou; John W D McDonald; Marjolijn Duijvestein; Jenny Jeyarajah; Claire E Parker; Tanja Van Viegen; Sigrid A Nelson; Brigid S Boland; Siddharth Singh; Parambir S Dulai; Mark A Valasek; Brian G Feagan; Vipul Jairath; William J Sandborn
Journal:  Aliment Pharmacol Ther       Date:  2020-09-27       Impact factor: 8.171

6.  Higher serum vitamin D levels are associated with protective serum cytokine profiles in patients with ulcerative colitis.

Authors:  John Gubatan; Shuji Mitsuhashi; Maria Serena Longhi; Talia Zenlea; Laura Rosenberg; Simon Robson; Alan C Moss
Journal:  Cytokine       Date:  2018-01-08       Impact factor: 3.861

7.  18F-FDG PET-MR enterography in predicting histological active disease using the Nancy index in ulcerative colitis: a randomized controlled trial.

Authors:  Yan Li; Benedikt Schaarschmidt; Lale Umutlu; Michael Forsting; Aydin Demircioglu; Anna Katharina Koch; Ole Martin; Ken Herrmann; Hendrik Juette; Andrea Tannapfel; Jost Langhorst
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-10-24       Impact factor: 9.236

8.  Fecal Calprotectin in Assessing Endoscopic and Histological Remission in Patients with Ulcerative Colitis.

Authors:  Wing Yan Mak; Anthony Buisson; Michael J Andersen; Donald Lei; Joel Pekow; Russell D Cohen; Stacy A Kahn; Bruno Pereira; David T Rubin
Journal:  Dig Dis Sci       Date:  2018-02-22       Impact factor: 3.199

Review 9.  Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials.

Authors:  A Cholapranee; G S Hazlewood; G G Kaplan; L Peyrin-Biroulet; A N Ananthakrishnan
Journal:  Aliment Pharmacol Ther       Date:  2017-03-22       Impact factor: 8.171

10.  The prognostic value of histology in ulcerative colitis in clinical remission with mesalazine.

Authors:  Giuseppe Frieri; Brigida Galletti; Mirko Di Ruscio; Rachele Tittoni; Annalisa Capannolo; Donatella Serva; Giovanni Latella; Laura Sollima; Pietro Leocata; Stefano Necozione; Rosamarie Frieri; Angelo Viscido
Journal:  Therap Adv Gastroenterol       Date:  2017-08-25       Impact factor: 4.409

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.